Osiris Therapeutics, Inc. announced the creation of a new biosurgery division focused on developing and marketing biological products for use in surgical procedures. The Biosurgery team will pursue introducing a new bone repair and regeneration products, termed XC. These products will utilize new manufacturing techniques to produce culture-expanded stem cells.

The goal of the XC project is to create a line of osteogenic products that can be used to treat a variety of orthopedic conditions.

Osiris Therapeutics is a stem cell therapeutic company focused on developing products to treat serious medical conditions in the inflammatory, orthopedic and cardiovascular areas.